Business Wire

PCI Pharma Services Introduces First-of-its-Kind Digital Platform to Provide Clients with Real-Time Supply Chain Data and Analytics

28.9.2020 13:00:00 EEST | Business Wire | Press release

Share

PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider today announced the launch of pci | bridge, an innovative digital platform that will give customers immediate visibility into their clinical and commercial supply chain, and provide instantaneous data and insights to inform decision-making. Created using an agile development process whereby key clients collaborated and provided input, PCI built an industry-leading digital interface that delivers greater transparency to clients – saving time and resources to ultimately help bring life-changing therapies to patients faster. The launch of pci | bridge is one of many initiatives that PCI has undertaken to incorporate digital transformation as core to its business strategy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200928005059/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

pci | bridge digital platform logo (Photo: Business Wire)

“At PCI, we are always looking to the future and could see the potential that technology and digital systems held for the pharmaceutical supply chain industry,” said Salim Haffar, Chief Executive Officer, PCI Pharma Services. “Twelve months ago, we made the deliberate decision as an organization to invest more in this area, with the goal of enhancing client experiences, digitizing business processes and aligning our IT to scale as we grow. The launch of pci | bridge represents a key milestone achievement in our digital transformation journey. We believe our unique offering will simplify how our clients interact with us and create a leading-edge client experience.”

A direct connection between PCI and clients, the platform will make real-time information readily accessible to clients including inventory, production, distribution and shipping data, presented in organized, customizable formats. The platform also features a document repository where electronic paperwork can be stored and accessed in one place, and signatures secured on the platform.

“Having a fully functioning supply chain, whose foundation is built on digitally-enabled capabilities and technologies, means we can be more adept at moving resources, assets and inventory – quickly and effectively,” said Wayne Hull, Chief Digital and Technology Officer, PCI Pharma Services. “We are embracing new technologies at PCI because they improve client experiences, give greater visibility into the supply chain, and provide data insights to optimize efficiencies and mitigate risks.”

The technology behind pci | bridge will closely and very securely integrate PCI’s systems with those of clients so that the supply chain can be easily managed by both parties. One significant advantage is removing manual processes that are often time intensive for both sides.

“Seeking input from multiple customers to understand how we hope to use the platform and previewing iterations with us is invaluable in terms of structuring the tool so it can actually be helpful to our work,” said Wendy Xia, Senior Director, Head of Supply Chain at Agios Pharmaceuticals, a key PCI client who collaborated with the company on pci | bridge. “I am very excited about my team using pci | bridge because I think it will greatly increase productivity and efficiency on both ends.”

“The benefits I see of using pci | bridge is that is that it eliminates the need for clients to constantly reach out to the project teams for updates. Now, we will have that information at our fingertips and can instead focus on the bigger picture with PCI, such as what’s coming next,” added Kevin Gregorczyk, Director, Development Operations at eFFECTOR Therapeutics, another key PCI client who participated in the development process.

Post-launch, PCI will continue to evolve and update pci | bridge features to meet client needs.

To learn more about pci | bridge, click here.

About PCI Pharma Services

The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enable us to address global development needs throughout the product life cycle — from Phase I Clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pci.com or follow us on Twitter at @PCI_Social.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Bailey Watroba, WE Communications
bwatroba@we-worldwide.com / +1-617-234-4110

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience23.2.2026 16:13:00 EET | Press release

Parents who have looked for the best birthday party idea for their children have had their wish fulfilled. Today, the Empire State Building (ESB) announced the debut of its first-ever ESB Birthday Party Package for kids at the international icon’s Observatory as part of year-long 95th anniversary celebrations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223161708/en/ The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience “From Lego playtime to Percy Jackson readers, children love the Empire State Building and now parents can give an unmatched experience to their children and their friends,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. “This birthday party package tops them all with an escorted visit through our world-famous Observatory, a private party room with a Ghirardelli sundae chef, Empire State Building party

CoolMPS™ 600: Accurate and Affordable Long MPS/NGS Reads on a Mid-Throughput Platform23.2.2026 16:00:00 EET | Press release

Swiss Rockets AG announces that its CoolMPS 600 mid-throughput sequencer with advanced chemistry and novel MPS/NGS read length will become available in Q2 2026. Enabled by its exclusive license of CoolMPS technology, Swiss Rockets AG is developing its first sequencer, CoolMPS 600, through contract R&D with Complete Genomics since August 2025. The platform is utilizing the company’s proprietary antibody-based CoolMPS™ chemistry combined with DNBSEQ™, a real PCR-free DNA nanoarray technology. Separately, Swiss Rockets AG announced that it has entered into a definitive agreement to acquire 100% ownership of Complete Genomics. CoolMPS 600 enables cost-effective extended single-end sequencing to 600 bases (SE600) while maintaining high base accuracy. The system is designed to support advanced whole-genome sequencing (WGS) with improved mapping accuracy across complex genomic regions, including better detection of structural variants. It also enables full length transcriptomes and more infor

Xsolla Co-Sponsors Gamescom Dev Leadership Summit in Lisbon, Bringing Together Gaming Industry Leaders to Shape the Future of Game Development23.2.2026 16:00:00 EET | Press release

Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its co-sponsorship of the Gamescom Dev Leadership Summit Lisbon, taking place February 24-26 at SUD Lisboa in Portugal. The event brings together gaming industry executives, studio founders, and business leaders to explore opportunities and innovations shaping the future of game development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223253705/en/ Graphic: Xsolla As part of its sponsorship, Xsolla will host the summit's Wednesday evening networking dinner and co-moderate a strategic roundtable session focused on business models and sustainable growth in the gaming industry. "We're seeing incredible innovation from studios across Europe as they build more direct relationships with their players and explore new ways to grow their businesses," said Berkley Egenes, Chief Marketing & Growth Officer at

Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies23.2.2026 15:08:00 EET | Press release

Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223465174/en/ Under the terms of the multi-year agreement, Quiver will receive an undisclosed advance payment and support for defined research activities along with additional licensing fees granting Angelini Pharma exclusive access to collaboration-generated data during the research term. Quiver is also eligible to receiv

Armis Achieves U.S. Department of Defense Impact Level 5 Authorization23.2.2026 15:00:00 EET | Press release

Armis, the cyber exposure management & security company, today announced that it has achieved authorization from the U.S. DoD’s Defense Information Systems Agency (DISA) to operate at an Impact Level 5 (IL5). This means that Armis has met strict requirements to manage and secure the DoD’s critical infrastructure, including Controlled Unclassified Information (CUI) systems. “We are committed to helping Federal agencies like the Department of Defense address their toughest cybersecurity challenges,” said Alex Mosher, President and CRO at Armis. “Achieving DISA IL5 authorization is an important milestone for Armis as we continue to support DoD customers in safeguarding critical systems, sensitive data and national security infrastructure from evolving cyber threats.” Armis empowers Federal agencies to build and optimize comprehensive cybersecurity programs with Armis Centrix™, the FedRAMP and DISA IL authorized Cyber Exposure Management Platform. The company previously achieved FedRAMP Mo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye